

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 11, 2009 (June 9, 2009)

**Lifevantage Corporation**

(Exact name of registrant as specified in its charter)

<b>Colorado</b> (State or other Jurisdiction of Incorporation)	<b>000-30489</b> (Commission File Number)	<b>90-0224471</b> (IRS Employer Identification No.)
<b>11545 W. Bernardo Court, Suite 301, San Diego, California</b> (Address of Principal Executive Offices)		<b>92127</b> (Zip Code)

Registrant's telephone number, including area code: **(858) 312-8000**

\_\_\_\_\_  
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On June 11, 2009, Lifevantage Corporation (the “Company”) announced that the Board of Directors of the Company has appointed Carrie E. Carlander as Chief Financial Officer of the Company effective June 9, 2009. The press release announcing the appointment is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Ms. Carlander most recently served as Chief Financial Officer of Genelux Corporation. Prior to Genelux, Ms. Carlander served as Chief Financial Officer for Adventrx Pharmaceuticals. She has also served in the role of Vice President Finance for V-Enable, Inc. and Websense Inc. Ms. Carlander has an MBA in Finance and Management from San Diego State University, a Bachelor’s Degree from the University of California at San Diego and is a Certified Management Accountant. Ms. Carlander will be entitled to an annual base salary of \$200,000.

**Item 7.01 Regulation FD Disclosure.**

On June 11, 2009, the Company issued a press release entitled “Carrie Carlander Joins LifeVantage as Chief Financial Officer.” The press release is attached as Exhibit 99.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit 99.1 Press Release, dated June 11, 2009, entitled “Carrie Carlander Joins LifeVantage as Chief Financial Officer.”

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 11, 2009

LIFEVANTAGE CORPORATION

By: /s/ Bradford K. Amman

Bradford K. Amman

Secretary/Treasurer

---

**EXHIBIT INDEX**

**Exhibit No.**

**Description**

---

99.1	Press Release, dated June 11, 2009, entitled "Carrie Carlander Joins LifeVantage as Chief Financial Officer."
------	---

**FOR IMMEDIATE RELEASE**

June 11, 2009

**NEWS**  
OTCBB: LFDN

**Contact: Jan Strobe**  
**(619) 890-4040**  
**Jean Golden**  
**(612) 385-2324**

**Carrie Carlander Joins LifeVantage as Chief Financial Officer**

SAN DIEGO, CA, June 11, 2009 — LifeVantage Corporation (OTCBB: LFDN), maker of Protandim®, today announced the Board of Directors has approved the appointment of Carrie Carlander as Chief Financial Officer.

Ms. Carlander most recently served as Chief Financial Officer of Genelux Corporation. Prior to Genelux, Ms. Carlander served as Chief Financial Officer for Adventrx Pharmaceuticals. She has also served in the role of Vice President Finance for V-Enable, Inc. and Websense Inc. Ms. Carlander has an MBA in Finance and Management from San Diego State University, a Bachelor's Degree from the University of California at San Diego and is a Certified Management Accountant.

"I am very pleased that Carrie has joined LifeVantage," said David W. Brown, President and CEO of LifeVantage Corporation. "Her impressive background and track record with dynamic public companies and her proven abilities in corporate governance, strategic planning, investor relations, and finance, will be a tremendous asset to LifeVantage."

"I am excited and honored to join the LifeVantage team, as I feel this is a company with tremendous growth potential. I look forward to joining David and the rest of the management team in building upon the great momentum the Company has recently generated through its launch into the network marketing channel and its rapid attraction of thousands of independent distributors," said Ms. Carlander.

-More-

---

## **LifeVantage Corporation**

LifeVantage Corporation is a publicly traded (OTCBB: LFVN), science-based, natural products company, dedicated to helping people reach their health and wellness goals through science-based solutions to oxidative stress. Founded in 2003 and based in San Diego, CA, LifeVantage develops nutraceutical products, including **Protandim®**, that leverage the company's expertise and that are intended to deliver significant health benefits to consumers. For more information, visit [www.LifeVantage.com](http://www.LifeVantage.com).

*This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company uses the words "anticipate," "believe," "could," "should," "estimate," "expect," "intend," "may," "predict," "project," "plan," "target" and similar terms and phrases, including references to assumptions, to identify forward-looking statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, the risk that government regulators and regulations could adversely affect our business; future laws or regulations may hinder or prohibit the production or sale of our existing product and any future products; unfavorable publicity could materially hurt our business; and the Company's ability to protect our intellectual property rights and the value of our product. These and other risk factors are discussed in greater detail in the Company's Annual Report on Form 10-KSB under the caption "Risk Factors", and in other documents filed the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.*

###

Note to Editors: Contact Jan Strode at 619-890-4040 or Jean Golden 612-385-2324 for interviews, photography, and other requests.